Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
JP Stock MarketDetailed Quotes
4565 Nxera Pharma
- 934
- +18+1.97%
20min DelayMarket Closed May 2 15:30 JST
83.97BMarket Cap-17.32P/E (Static)
947High906Low1.06MVolume914Open916Pre Close983.01MTurnover175452wk High1.48%Turnover Ratio89.90MShares66852wk Low-53.92EPS TTM66.74BFloat Cap6545Historical HighLossP/E (Static)71.45MShs Float23Historical Low-53.92EPS LYR4.48%Amplitude--Dividend TTM1.23P/B100Lot Size--Div YieldTTM
Nxera Pharma News
Nxera Pharma: Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Nxera Pharma: Consolidated Financial Results for the Three months Ended March 31, 2025 (IFRS)
Nxera Pharma: Nxera’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Nxera Pharma: Announcement of the commencement of phase 3 trials of NBI-1117568 targeting adult schizophrenia patients by Neurocline, our partner
Nxera Pharma: Notice of Issuance of New Shares Under RSU Plan and Determination of Pmt Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU
Nxera Pharma: Notice regarding the new management system
Nxera Pharma: Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Nxera Pharma: Our partner Tempero Bio has begun phase 2 testing of TMP-301 targeting alcoholism
Nxera Pharma: Independent Officer Registration Form
Nxera Pharma: Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Nxera Pharma: Transfer of rights in Japan and APAC (excluding China) for autoimmune disease treatment candidate Cenerimod to Viatris
Nxera Pharma: Correction to “Notice Regarding Reduction of the Amount of Capital Reserve and Disposition of Surplus”
Nxera Pharma: (Correction) Partial Corrections to the “Notice Concerning Decrease in the Amount of Capital Reserves and Appropriation of Surplus Funds”
Nxera Pharma: Notice Regarding Reduction of the Amount of Capital Reserve and Disposition of Surplus
Nxera Pharma: Notice Concerning Decrease in Capital Reserve Amount and Appropriation of Surplus
Nxera Pharma: Consolidated Financial Results for the FY2024 (IFRS)
Nxera Pharma: Notice regarding partial changes to the Articles of Incorporation
Nxera Pharma: Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma: Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Nxera Pharma: Notice Regarding Partial Amendment to the Articles of Incorporation
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts